Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer

C. Sanchez, R. Chan, P. Bajgain, S. Rambally, G. Palapattu, M. Mims, C. M. Rooney, A. M. Leen, M. K. Brenner, J. F. Vera

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background:Prostate cancer remains a significant health problem for men in the Western world. Although treatment modalities are available, these do not confer long-term benefit and are accompanied by substantial side effects. Adoptive immunotherapy represents an attractive alternative to conventional treatments as a means to control tumor growth.Methods:To selectively target the tumor-expressed form of Muc1 we constructed a retroviral vector encoding a chimeric antigen receptor (CAR) directed against the aberrantly-expressed extracellular portion of Muc1 called the 'variable number of tandem repeats'.Results:We now demonstrate that T cells can be genetically engineered to express a CAR targeting the tumor-associated antigen Muc1. CAR-Muc1 T cells were able to selectively kill Muc1-expressing human prostate cancer cells. However, we noted that heterogeneous expression of the Muc1 antigen on tumor cells facilitated immune escape and the outgrowth of target-antigen loss variants of the tumor. Given the importance of androgen ablation therapy in the management of metastatic prostate cancer, we therefore also tested the value of combining conventional (anti-androgen) and experimental (CAR-Muc1 T cells) approaches. We show that CAR-Muc1 T cells were not adversely impacted by anti-androgen therapy and subsequently demonstrate the feasibility of combining the approaches to produce additive anti-tumor effects in vitro.Conclusions: Adoptive transfer of CAR-Muc1 T cells alone or in combination with other luteinizing hormone-releasing hormone analogs or antagonists should be tested in human clinical trials.

Original languageEnglish (US)
Pages (from-to)123-131
Number of pages9
JournalProstate Cancer and Prostatic Diseases
Volume16
Issue number2
DOIs
StatePublished - Jun 2013

Fingerprint

T-Cell Antigen Receptor
Immunotherapy
Androgens
Prostatic Neoplasms
T-Lymphocytes
Antigen Receptors
Neoplasm Antigens
Neoplasms
Men's Health
Adoptive Immunotherapy
Minisatellite Repeats
Western World
Adoptive Transfer
Therapeutics
Gonadotropin-Releasing Hormone
Clinical Trials
Antigens
Growth

Keywords

  • CAR T cells
  • combination therapy
  • immunotherapy
  • tumor immune escape

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. / Sanchez, C.; Chan, R.; Bajgain, P.; Rambally, S.; Palapattu, G.; Mims, M.; Rooney, C. M.; Leen, A. M.; Brenner, M. K.; Vera, J. F.

In: Prostate Cancer and Prostatic Diseases, Vol. 16, No. 2, 06.2013, p. 123-131.

Research output: Contribution to journalArticle

Sanchez, C, Chan, R, Bajgain, P, Rambally, S, Palapattu, G, Mims, M, Rooney, CM, Leen, AM, Brenner, MK & Vera, JF 2013, 'Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer', Prostate Cancer and Prostatic Diseases, vol. 16, no. 2, pp. 123-131. https://doi.org/10.1038/pcan.2012.49
Sanchez, C. ; Chan, R. ; Bajgain, P. ; Rambally, S. ; Palapattu, G. ; Mims, M. ; Rooney, C. M. ; Leen, A. M. ; Brenner, M. K. ; Vera, J. F. / Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. In: Prostate Cancer and Prostatic Diseases. 2013 ; Vol. 16, No. 2. pp. 123-131.
@article{3f7d08d316834e93a78b7b3cf4841f57,
title = "Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer",
abstract = "Background:Prostate cancer remains a significant health problem for men in the Western world. Although treatment modalities are available, these do not confer long-term benefit and are accompanied by substantial side effects. Adoptive immunotherapy represents an attractive alternative to conventional treatments as a means to control tumor growth.Methods:To selectively target the tumor-expressed form of Muc1 we constructed a retroviral vector encoding a chimeric antigen receptor (CAR) directed against the aberrantly-expressed extracellular portion of Muc1 called the 'variable number of tandem repeats'.Results:We now demonstrate that T cells can be genetically engineered to express a CAR targeting the tumor-associated antigen Muc1. CAR-Muc1 T cells were able to selectively kill Muc1-expressing human prostate cancer cells. However, we noted that heterogeneous expression of the Muc1 antigen on tumor cells facilitated immune escape and the outgrowth of target-antigen loss variants of the tumor. Given the importance of androgen ablation therapy in the management of metastatic prostate cancer, we therefore also tested the value of combining conventional (anti-androgen) and experimental (CAR-Muc1 T cells) approaches. We show that CAR-Muc1 T cells were not adversely impacted by anti-androgen therapy and subsequently demonstrate the feasibility of combining the approaches to produce additive anti-tumor effects in vitro.Conclusions: Adoptive transfer of CAR-Muc1 T cells alone or in combination with other luteinizing hormone-releasing hormone analogs or antagonists should be tested in human clinical trials.",
keywords = "CAR T cells, combination therapy, immunotherapy, tumor immune escape",
author = "C. Sanchez and R. Chan and P. Bajgain and S. Rambally and G. Palapattu and M. Mims and Rooney, {C. M.} and Leen, {A. M.} and Brenner, {M. K.} and Vera, {J. F.}",
year = "2013",
month = "6",
doi = "10.1038/pcan.2012.49",
language = "English (US)",
volume = "16",
pages = "123--131",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer

AU - Sanchez, C.

AU - Chan, R.

AU - Bajgain, P.

AU - Rambally, S.

AU - Palapattu, G.

AU - Mims, M.

AU - Rooney, C. M.

AU - Leen, A. M.

AU - Brenner, M. K.

AU - Vera, J. F.

PY - 2013/6

Y1 - 2013/6

N2 - Background:Prostate cancer remains a significant health problem for men in the Western world. Although treatment modalities are available, these do not confer long-term benefit and are accompanied by substantial side effects. Adoptive immunotherapy represents an attractive alternative to conventional treatments as a means to control tumor growth.Methods:To selectively target the tumor-expressed form of Muc1 we constructed a retroviral vector encoding a chimeric antigen receptor (CAR) directed against the aberrantly-expressed extracellular portion of Muc1 called the 'variable number of tandem repeats'.Results:We now demonstrate that T cells can be genetically engineered to express a CAR targeting the tumor-associated antigen Muc1. CAR-Muc1 T cells were able to selectively kill Muc1-expressing human prostate cancer cells. However, we noted that heterogeneous expression of the Muc1 antigen on tumor cells facilitated immune escape and the outgrowth of target-antigen loss variants of the tumor. Given the importance of androgen ablation therapy in the management of metastatic prostate cancer, we therefore also tested the value of combining conventional (anti-androgen) and experimental (CAR-Muc1 T cells) approaches. We show that CAR-Muc1 T cells were not adversely impacted by anti-androgen therapy and subsequently demonstrate the feasibility of combining the approaches to produce additive anti-tumor effects in vitro.Conclusions: Adoptive transfer of CAR-Muc1 T cells alone or in combination with other luteinizing hormone-releasing hormone analogs or antagonists should be tested in human clinical trials.

AB - Background:Prostate cancer remains a significant health problem for men in the Western world. Although treatment modalities are available, these do not confer long-term benefit and are accompanied by substantial side effects. Adoptive immunotherapy represents an attractive alternative to conventional treatments as a means to control tumor growth.Methods:To selectively target the tumor-expressed form of Muc1 we constructed a retroviral vector encoding a chimeric antigen receptor (CAR) directed against the aberrantly-expressed extracellular portion of Muc1 called the 'variable number of tandem repeats'.Results:We now demonstrate that T cells can be genetically engineered to express a CAR targeting the tumor-associated antigen Muc1. CAR-Muc1 T cells were able to selectively kill Muc1-expressing human prostate cancer cells. However, we noted that heterogeneous expression of the Muc1 antigen on tumor cells facilitated immune escape and the outgrowth of target-antigen loss variants of the tumor. Given the importance of androgen ablation therapy in the management of metastatic prostate cancer, we therefore also tested the value of combining conventional (anti-androgen) and experimental (CAR-Muc1 T cells) approaches. We show that CAR-Muc1 T cells were not adversely impacted by anti-androgen therapy and subsequently demonstrate the feasibility of combining the approaches to produce additive anti-tumor effects in vitro.Conclusions: Adoptive transfer of CAR-Muc1 T cells alone or in combination with other luteinizing hormone-releasing hormone analogs or antagonists should be tested in human clinical trials.

KW - CAR T cells

KW - combination therapy

KW - immunotherapy

KW - tumor immune escape

UR - http://www.scopus.com/inward/record.url?scp=84882449121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882449121&partnerID=8YFLogxK

U2 - 10.1038/pcan.2012.49

DO - 10.1038/pcan.2012.49

M3 - Article

C2 - 23295316

AN - SCOPUS:84882449121

VL - 16

SP - 123

EP - 131

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 2

ER -